title: [A "newborn" to complete the family of anticholinergics].
abstract: Emergence of a new ultra-long acting anticholinergic as glycopyrronium can bring a change of attitude in the life of practitioner. In this article I try to correctly position the new representative of the anticholinergics class, looking at all the evidence in vitro and in viva, benefits, tolerability and safety of this product. Finally, on scientific evidence-based medicine I positioned this product in the new GOLD 2011 classification.
authors.affiliation: Institutulde Pneumologie, Marius Nasta, Bucureşti. mihaltan@starnets.ro
authors.forename: Florin
authors.initials: F
authors.lastname: Mihălţan
mesh_terms: D001993:Bronchodilator Agents / Q000627:therapeutic use*; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006024:Glycopyrrolate / Q000627:therapeutic use*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011788:Quality of Life; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents; D018680:Cholinergic Antagonists; D006024:Glycopyrrolate